Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FF EAI Robotics Ecosystem Inc.RTTR · Entity 7776 | Director | January 21, 2020 | April 23, 2020 |
| OmniAb, Inc.OABI · Entity 5294 | Director · President and CEO | April 07, 2026 | April 08, 2026 |
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FF EAI Robotics Ecosystem Inc.
Report date January 21, 2020 · Filed April 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 138,635 |
Ending reported balance
After 2020-04-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-01-21 · Conversion · Acquired 76,923 · Balance 100,174 F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. Row 2 · 2020-04-10 · Grant · Acquired 38,461 · Balance 138,635 F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.30 | Direct | 0 |
Reported balance
After 2020-01-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-21 · Conversion · Disposed 100 · Balance 0 F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. |
| Warrant Shares (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2023-11-05 | Direct | 0 |
Reported balance
After 2020-04-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-04-10 · Disposition to issuer · Disposed 38,461 · Balance 0 F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date.
F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended.
OmniAb, Inc.
Report date April 07, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,420,492 |
Ending reported balance
After 2026-04-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-07 · Exercise / conversion · Acquired 36,459 · Balance 4,439,736 F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-04-07 · Sale · Disposed 19,244 · Balance 4,420,492 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 309,376 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Exercise / conversion · Disposed 36,459 · Balance 309,376 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Viking Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 135,186 |
Ending reported balance
After 2026-01-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-02 · Exercise / conversion · Acquired 16,000 · Balance 148,036 Row 2 · 2026-01-02 · Sale · Disposed 16,000 · Balance 132,036 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2026-01-02 · Grant · Acquired 3,150 · Balance 135,186 F2: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2026-01-04 | Direct | 0 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Exercise / conversion · Disposed 16,000 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42 · Expires 2036-01-02 | Direct | 20,400 |
Reported balance
After 2026-01-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-02 · Grant · Acquired 20,400 · Balance 20,400 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LIGAND PHARMACEUTICALS INC
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,187 |
Reported balance
After 2022-11-01 transaction · row 1
1 source rowRow 1 · 2022-11-01 · Disposition to issuer · Disposed 20,304 · Balance 162,187 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 34,214 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
OmniAb Operations, Inc.
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 212,362 |
Reported balance
After 2022-11-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-01 · Grant · Acquired 26,193 · Balance 212,362 F1: Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F2: Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 212,362 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05 | Direct | 60,878 |
Reported balance
After 2022-11-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-01 · Grant · Acquired 60,878 · Balance 60,878 F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-01 · Disposition to issuer · Disposed 60,878 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $41.82 · Expires 2024-02-12 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-01 · Disposition to issuer · Disposed 55,222 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2025-02-10 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-01 · Disposition to issuer · Disposed 35,258 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.21 · Expires 2026-02-11 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-11-01 · Disposition to issuer · Disposed 22,660 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $56.41 · Expires 2027-02-24 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-11-01 · Disposition to issuer · Disposed 21,271 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $89.36 · Expires 2028-03-02 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-11-01 · Disposition to issuer · Disposed 17,711 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $66.30 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-11-01 · Disposition to issuer · Disposed 29,861 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $53.77 · Expires 2030-02-13 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-11-01 · Disposition to issuer · Disposed 29,012 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $99.75 · Expires 2031-02-03 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-11-01 · Disposition to issuer · Disposed 11,475 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.
F2: Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9.
F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.
F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.
F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
F6: The stock option is fully vested and exercisable.
F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.
F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.
F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2019 Filed Jun 12, 2019 22:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,004 | $21.92 | $22,007.68 |
DisclosureSEC source: 0000886163-19-000114 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 18:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,894 | $0.00 Strike: $9.97 | $0.00 |
DisclosureSEC source: 0000886163-19-000055 · edgardoc.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,001 Underlying: Common Stock · 14,894 shares Expires 2021-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 04/18/11. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 18:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 14,894 | $9.97 | $148,493.18 |
DisclosureSEC source: 0000886163-19-000055 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2019 Filed Apr 24, 2020 23:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 642 | $120.86 | $77,592.12 |
DisclosureSEC source: 0000886163-20-000051 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,727 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018. Read SEC document |
| February 15, 2019 Filed Apr 24, 2020 23:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,246 | $120.86 | $150,591.56 |
DisclosureSEC source: 0000886163-20-000051 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,369 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017. Read SEC document |
| February 15, 2019 Filed Apr 24, 2020 23:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 938 | $120.86 | $113,366.68 |
DisclosureSEC source: 0000886163-20-000051 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,615 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 34,181 | $0.00 Strike: $117.97 | $0.00 |
DisclosureSEC source: 0000886163-19-000036 · edgardoc.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,181 Underlying: Common Stock · 34,181 shares Expires 2029-03-02 F1 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/19. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 7,472 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000036 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,553 Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:27 UTC | FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001382963-19-000022 · edgar.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-02-06 F1 · derivative.exercise_date: The option vests in twelve (12) equal monthly installments beginning on March 6, 2019 with the balance vesting on the 6th day of each calendar month thereafter until vested in full. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,284 | $111.78 | $143,525.52 |
DisclosureSEC source: 0000886163-19-000018 · edgardoc.xml · nonDerivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,081 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 3,715 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000018 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,365 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/29/2017 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2018. On January 23, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,284 | $111.78 | $143,525.52 |
DisclosureSEC source: 0000886163-19-000018 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,650 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 3,547 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000018 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,934 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 02/11/2016 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2018. On January 23, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 01:26 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001209191-19-001563 · doc4.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-01-02 Read SEC document |
| December 12, 2018 Filed Dec 12, 2018 22:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,999 | $0.00 Strike: $9.97 | $0.00 |
DisclosureSEC source: 0000886163-18-000168 · edgardoc.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,895 Underlying: Common Stock · 7,999 shares Expires 2021-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 04/18/11. Read SEC document |
| December 12, 2018 Filed Dec 12, 2018 22:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 7,999 | $9.97 | $79,750.03 |
DisclosureSEC source: 0000886163-18-000168 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 23:24 UTC | FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776 | PurchaseWarrant Shares (right to buy) · Derivative | 38,461 | Not disclosed Strike: $1.30 | Not disclosed |
DisclosureSEC source: 0001382963-18-000144 · edgar.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,461 Underlying: Common Stock · 38,461 shares Expires 2023-11-05 F2 · price: The Reporting Person purchased the shares of Series B convertible preferred stock (the "Series B Shares") from the Issuer in a private placement by the Issuer at a stated price of $1,000 per share and received, in addition to the Series B Shares, a warrant to purchase a number of shares of common stock equal to 50% of the aggregate number of shares of common stock into which his Series B Shares are initally convertible, for no additional consideration. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 23:24 UTC | FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776 | PurchaseSeries B convertible preferred stock · Derivative | 100 | Not disclosed Strike: $1.30 | Not disclosed |
DisclosureSEC source: 0001382963-18-000144 · edgar.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Underlying: Common Stock · 76,923 shares Expires not disclosed F2 · price: The Reporting Person purchased the shares of Series B convertible preferred stock (the "Series B Shares") from the Issuer in a private placement by the Issuer at a stated price of $1,000 per share and received, in addition to the Series B Shares, a warrant to purchase a number of shares of common stock equal to 50% of the aggregate number of shares of common stock into which his Series B Shares are initally convertible, for no additional consideration. F1 · derivative.expiration_date: The Series B convertible preferred stock has no expiration date. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 22:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000886163-18-000140 · edgardoc.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,675 Underlying: Common Stock · 12,000 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 24, 2018, in accordance with Rule 10b5-1. F4 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 22:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,088 | $0.00 Strike: $9.97 | $0.00 |
DisclosureSEC source: 0000886163-18-000140 · edgardoc.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,894 Underlying: Common Stock · 2,088 shares Expires 2021-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 22:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 12,000 | $273.88 | $3,286,560.00 |
DisclosureSEC source: 0000886163-18-000140 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,388 F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 24, 2018, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.12 to $276.98, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 22:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 12,000 | $14.47 | $173,640.00 |
DisclosureSEC source: 0000886163-18-000140 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 24, 2018, in accordance with Rule 10b5-1. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 22:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,088 | $9.97 | $20,817.36 |
DisclosureSEC source: 0000886163-18-000140 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000886163-18-000133 · edgardoc.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,675 Underlying: Common Stock · 12,000 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 24, 2018, in accordance with Rule 10b5-1. F4 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,044 | $0.00 Strike: $9.97 | $0.00 |
DisclosureSEC source: 0000886163-18-000133 · edgardoc.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,982 Underlying: Common Stock · 1,044 shares Expires 2021-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 12,000 | $255.01 | $3,060,081.60 |
DisclosureSEC source: 0000886163-18-000133 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,300 F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 24, 2018, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.11 to $260.43, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 12,000 | $14.47 | $173,640.00 |
DisclosureSEC source: 0000886163-18-000133 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 24, 2018, in accordance with Rule 10b5-1. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,044 | $9.97 | $10,408.68 |
DisclosureSEC source: 0000886163-18-000133 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2018 Filed Aug 20, 2018 21:19 UTC | FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776 | PurchaseCommon Stock | 19,751 | $2.04 | $40,292.04 |
DisclosureSEC source: 0001382963-18-000125 · edgar.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,751 Read SEC document |
| August 17, 2018 Filed Sep 19, 2018 18:19 UTC Amendment | FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776 | PurchaseCommon Stock | 19,751 | $2.04 | $40,292.04 |
DisclosureSEC source: 0001382963-18-000131 · edgar.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,251 F1 · balance_after: The previous Form 4 filed on August 20, 2018 did not reflect the Issuer's recent reverse stock split and inadvertently overstated the amount of securities beneficially owned by the Reporting Person following the reported transaction. The number included here has been updated to reflect such reverse stock split. Read SEC document |
| May 10, 2018 Filed May 11, 2018 21:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,881 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000886163-18-000067 · edgardoc.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,675 Underlying: Common Stock · 8,881 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12. Read SEC document |
| May 10, 2018 Filed May 11, 2018 21:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,055 | $0.00 Strike: $9.97 | $0.00 |
DisclosureSEC source: 0000886163-18-000067 · edgardoc.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,026 Underlying: Common Stock · 1,055 shares Expires 2021-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11. Read SEC document |
| May 10, 2018 Filed May 11, 2018 21:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,055 | $9.97 | $10,518.35 |
DisclosureSEC source: 0000886163-18-000067 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2018 Filed May 11, 2018 21:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 8,881 | $167.63 | $1,488,686.51 |
DisclosureSEC source: 0000886163-18-000067 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,201 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.60 to $167.805, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2018 Filed May 11, 2018 21:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 8,881 | $14.47 | $128,508.07 |
DisclosureSEC source: 0000886163-18-000067 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,457 | $165.87 | $241,672.59 |
DisclosureSEC source: 0000886163-18-000039 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,201 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| March 06, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 2,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-18-000039 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,658 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/11/2016 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the two-year performance period ending December 31, 2017. On March 05, 2018, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 20,274 | $0.00 Strike: $159.01 | $0.00 |
DisclosureSEC source: 0000886163-18-000039 · edgardoc.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,274 Underlying: Common Stock · 20,274 shares Expires 2028-03-02 F3 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 03/02/18. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 3,883 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-18-000039 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,718 Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,444 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000886163-18-000026 · edgardoc.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,556 Underlying: Common Stock · 5,444 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,004 | $0.00 Strike: $9.97 | $0.00 |
DisclosureSEC source: 0000886163-18-000026 · edgardoc.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,081 Underlying: Common Stock · 1,004 shares Expires 2021-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 5,444 | $152.98 | $832,823.66 |
DisclosureSEC source: 0000886163-18-000026 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,835 Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,444 | $14.47 | $78,774.68 |
DisclosureSEC source: 0000886163-18-000026 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,004 | $9.97 | $10,009.88 |
DisclosureSEC source: 0000886163-18-000026 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,246 | $157.18 | $195,846.28 |
DisclosureSEC source: 0000886163-18-000018 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,831 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 906 | $157.18 | $142,405.08 |
DisclosureSEC source: 0000886163-18-000018 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,077 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,511 | $157.18 | $237,498.98 |
DisclosureSEC source: 0000886163-18-000018 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,983 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/10/2015. Read SEC document |
| January 23, 2018 Filed Jan 26, 2018 02:18 UTC | FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001382963-18-000017 · edgar.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The option vests in twelve (12) equal monthly installments beginning on February 23, 2018 with the balance vesting on the 23rd day of each calendar month thereafter until vested in full. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:15 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-18-000834 · doc4.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-02 Read SEC document |
| December 28, 2017 Filed Dec 30, 2017 02:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,971 | $138.66 | $411,958.86 |
DisclosureSEC source: 0000886163-17-000159 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,494 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.